3B Blackbio Dx Limited Q1 FY26 earnings call summary

Earnings call of 19 Aug 2025, summarised by AI from the filing.

Management guides 15-20% MDX revenue growth for FY25-26 and 20-25% export growth for next 2-3 years.

Key takeaways

1. Guidance Management guides 15-20% MDX revenue growth for FY25-26 and 20-25% export growth for next 2-3 years.
2. Growth driver Coris AMR products and R&D pipeline expected to drive revenue to EUR7-8 million with 10-15% EBITDA margin in 3-4 years.
3. Margin risk EBITDA margin expected to decline towards 55% from 60% due to competition and wage inflation.

Original filing on BSE

3B Blackbio Dx Limited earnings call, investor presentation and press release summaries

• Q1 FY27: Results deck (13 Aug 2026)
• Q4 FY26: Earnings call (1 Jun 2026), Results deck (29 May 2026)
• Q3 FY26: Earnings call (21 Feb 2026), Results deck (6 Feb 2026)
• Q2 FY26: Results deck (13 Nov 2025)
• Q1 FY26: Earnings call (19 Aug 2025)
• Q4 FY25: Results deck (28 May 2025)
• Other events: Strategy deck (14 Aug 2025)